Satellos Bioscience Inc. announced that it will receive CAD 44,545,796 ($33,292,573) in funding on May 10, 2023. The company will issue Convertible Preferred Shares in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.48 CAD | +9.09% | -7.69% | +11.63% |
Mar. 27 | Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 27 | Satellos Bioscience Announces FY 2023 Results | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.63% | 39.55M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- MSCL Stock
- News Satellos Bioscience Inc.
- Satellos Bioscience Inc. announced that it expects to receive CAD 44.545796 million in funding